RAPT Therapeutics, Inc.
561 Eccles Avenue
South San Francisco, California, 94080
June 27, 2022
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Joshua Gorsky
| Re: | RAPT Therapeutics, Inc. |
Registration Statement on Form S-3 Filed June 24, 2022
File No. 333-265812
To whom it may concern:
Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, RAPT Therapeutics, Inc. (the “Company”) hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-265812) be accelerated by the Securities and Exchange Commission to 4:00 p.m. Washington D.C. time on June 29, 2022 or as soon as practicable thereafter.
The Company requests that we be notified of such effectiveness by a telephone call to Courtney M.W. Tygesson of Cooley LLP at (312) 881-6500 and that such effectiveness also be confirmed in writing.
| Very truly yours, | ||
| RAPT Therapeutics, Inc. | ||
| By: | /s/ Rodney Young | |
| Rodney Young | ||
| Chief Financial Officer | ||
| cc: | Courtney M.W. Tygesson, Cooley LLP |
